Basavana Goudra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Basavana Goudra has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Preet Mohinder Singh
Department of Anaesthesiology, Washington University in Saint Louis/Barnes Jewish Hospital, Saint Louis, MO, USA
30 shared publications Preet Mohinder Singh
Washington University in Saint Louis
15 shared publications- Michael Stuart Green
Department of Anesthesiology and Perioperative Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
8 shared publications Gowri Gouda
Burrel College of Osteopathic Medicine, 3501 Arrowhead Drive, Las Cruces, NM, 88001, USA
7 shared publicationsAnuradha Borle
Department of Anesthesia, All Institute of Medical Sciences, New Delhi, India
6 shared publicationsDivakara Gouda
Department of Internal Medicine, Inspira Health Network, Mullica Hill, United States
6 shared publications
Latest Publications
- 22 October 2026
- Published by Wolters Kluwer Health in International Anesthesiology Clinics
The Evolving Landscape of Non-Operating Room Anesthesia: Procedural Advances and Operational Implications
Was not provided for this article.
- 22 October 2026
- Published by Wolters Kluwer Health in International Anesthesiology Clinics
The Evolving Landscape of Non-Operating Room Anesthesia: Procedural Advances and Operational Implications
Was not provided for this article.
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Journal of Indian College of Anaesthesiologists
- Vol. 5 (2) , 146-148
Intraosseous Access as the Sole Vascular Route for Emergency Laparotomy in Septic Shock: A Case Report with Perioperative Implications
Failure to obtain vascular access in critically ill surgical patients represents a rare but life-threatening perioperative challenge. Intraosseous (IO) access is well established in emergency resuscitation but is seldom used as the primary vascular route during adult anesthesia. We describe a 63-year-old morbidly obese woman with septic shock secondary to gastrointestinal perforation and concurrent coronavirus disease 2019 infection in whom peripheral intravenous, central venous, and arterial access attempts failed despite repeated ultrasound-guided efforts by experienced clinicians. A proximal tibial IO line was established and served as the sole reliable vascular access for induction and maintenance of general anesthesia, vasopressor infusion, and administration of approximately 3 L of crystalloid during emergent exploratory laparotomy. The IO line remained functional postoperatively and enabled successful medication delivery during cardiac arrest, resulting in return of spontaneous circulation. Despite transient stabilization, the patient later died from multisystem organ failure. This case demonstrates that IO access can function as a dependable primary vascular route for anesthetic and resuscitative management during major adult surgery when conventional access is unobtainable. Early consideration of IO access may prevent delays in definitive surgical care in critically ill patients.
- 1 July 2026
- Published by Wolters Kluwer Health in Journal of Indian College of Anaesthesiologists
- Vol. 5 (2) , 146-148
Open AccessIntraosseous Access as the Sole Vascular Route for Emergency Laparotomy in Septic Shock: A Case Report with Perioperative Implications
Failure to obtain vascular access in critically ill surgical patients represents a rare but life-threatening perioperative challenge. Intraosseous (IO) access is well established in emergency resuscitation but is seldom used as the primary vascular route during adult anesthesia. We describe a 63-year-old morbidly obese woman with septic shock secondary to gastrointestinal perforation and concurrent coronavirus disease 2019 infection in whom peripheral intravenous, central venous, and arterial access attempts failed despite repeated ultrasound-guided efforts by experienced clinicians. A proximal tibial IO line was established and served as the sole reliable vascular access for induction and maintenance of general anesthesia, vasopressor infusion, and administration of approximately 3 L of crystalloid during emergent exploratory laparotomy. The IO line remained functional postoperatively and enabled successful medication delivery during cardiac arrest, resulting in return of spontaneous circulation. Despite transient stabilization, the patient later died from multisystem organ failure. This case demonstrates that IO access can function as a dependable primary vascular route for anesthetic and resuscitative management during major adult surgery when conventional access is unobtainable. Early consideration of IO access may prevent delays in definitive surgical care in critically ill patients.
- Open Access
- 15 April 2026
- Published by Wolters Kluwer Health in Annals of Cardiac Anaesthesia
- Vol. 29 (2) , 237-246
Anesthetic Management in Patients with Impella Devices: A Retrospective Review and Clinical Guide
Background: The Impella family of percutaneous a left ventricular assist devices are increasingly used for hemodynamic support in patients with cardiogenic shock or advanced heart failure. However, guidance on anesthetic management for patients with Impella support undergoing noncardiac procedures remains sparse. This study reviews perioperative practices and outcomes to inform clinical management. Methods: Following institutional review board approval, a retrospective analysis was performed of adult patients receiving an Impella device (2.5, CP, 5.0, or 5.5) at Thomas Jefferson University Hospital, Philadelphia, USA, between December 2017 and October 2024. Patients, who subsequently underwent procedures involving anesthesia care were included. Demographics, procedure type, anesthetic technique, pharmacologic management, hemodynamic support, and intraoperative outcomes were analyzed descriptively. Results: Among 165 Impella recipients, 41 underwent anesthesia requiring procedures: Eight gastrointestinal (GI) and 33 non-GI interventions. All GI cases involved Impella 5.5 devices, commonly for urgent endoscopy in gastrointestinal bleeding. General anesthesia was used in 50% of GI and 94% of non-GI cases. Propofol and etomidate were predominant induction agents; fentanyl and rocuronium were widely utilized. Phenylephrine and norepinephrine were the most frequent vasopressors, with adjunctive use of dobutamine or epinephrine. No intraoperative device malfunctions, dislodgements, or arrests occurred. Conclusions: With individualized anesthetic planning and vigilant hemodynamic control, Impella-supported patients can safely undergo diverse procedures. Deep sedation may suffice for select endoscopic interventions, whereas complex non-GI operations generally require general anesthesia. These findings provide a foundation for developing standardized perioperative management protocols for this growing patient population.
- 15 April 2026
- Published by Wolters Kluwer Health in Annals of Cardiac Anaesthesia
- Vol. 29 (2) , 237-246
Open AccessAnesthetic Management in Patients with Impella Devices: A Retrospective Review and Clinical Guide
Background: The Impella family of percutaneous a left ventricular assist devices are increasingly used for hemodynamic support in patients with cardiogenic shock or advanced heart failure. However, guidance on anesthetic management for patients with Impella support undergoing noncardiac procedures remains sparse. This study reviews perioperative practices and outcomes to inform clinical management. Methods: Following institutional review board approval, a retrospective analysis was performed of adult patients receiving an Impella device (2.5, CP, 5.0, or 5.5) at Thomas Jefferson University Hospital, Philadelphia, USA, between December 2017 and October 2024. Patients, who subsequently underwent procedures involving anesthesia care were included. Demographics, procedure type, anesthetic technique, pharmacologic management, hemodynamic support, and intraoperative outcomes were analyzed descriptively. Results: Among 165 Impella recipients, 41 underwent anesthesia requiring procedures: Eight gastrointestinal (GI) and 33 non-GI interventions. All GI cases involved Impella 5.5 devices, commonly for urgent endoscopy in gastrointestinal bleeding. General anesthesia was used in 50% of GI and 94% of non-GI cases. Propofol and etomidate were predominant induction agents; fentanyl and rocuronium were widely utilized. Phenylephrine and norepinephrine were the most frequent vasopressors, with adjunctive use of dobutamine or epinephrine. No intraoperative device malfunctions, dislodgements, or arrests occurred. Conclusions: With individualized anesthetic planning and vigilant hemodynamic control, Impella-supported patients can safely undergo diverse procedures. Deep sedation may suffice for select endoscopic interventions, whereas complex non-GI operations generally require general anesthesia. These findings provide a foundation for developing standardized perioperative management protocols for this growing patient population.
- Open Access
- 16 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1569
Relationship Between Navigation Success, Diagnostic Accuracy, and Ventilation Strategy: Retrospective Chart Review of 224 Consecutive Navigational Bronchoscopic Procedures Performed Under General Anesthesia
Background: Navigational bronchoscopy (NB) enables precise sampling of peripheral and central pulmonary nodules using shape-sensing or electromagnetic guidance. A major challenge is anesthesia-induced atelectasis, which alters lung anatomy, reduces registration accuracy, and is known to lower diagnostic accuracy. To counteract this, ventilatory protocols such as the Ventilatory Strategy to Prevent Atelectasis (VESPA) and the Lung Navigation Ventilation Protocol (LNVP) have been recommended. Their adoption and clinical impact, however, remain uncertain. Methods: We conducted a retrospective review of 224 consecutive NB procedures performed under general anesthesia at a single academic medical center (January 2020–August 2024). Demographic, anesthetic, and ventilatory data were extracted from electronic records. Outcomes included navigational success (ability to reach the lesion) and diagnostic accuracy (concordance between bronchoscopic diagnosis and final clinical diagnosis after follow-up). Ventilatory practices were compared with published VESPA and LNVP recommendations. Results: Navigational success, defined as successful advancement of the bronchoscope to the target lesion with tissue acquisition, was achieved in 89.2% of cases. Overall diagnostic accuracy, defined as concordance between bronchoscopic diagnosis and final clinical diagnosis after follow-up, was 81.7%. Ventilatory management consistently diverged from recommended protocols. Most patients were ventilated with FiO2 > 0.6, PEEP in the range of 7–10 cm H2O, and tidal volumes of 300–500 mL. The only recommended maneuver systematically applied was recruitment immediately after intubation. Despite widespread deviation from both VESPA and LNVP, diagnostic performance remained favorable relative to published benchmarks. No major anesthesia-related complications occurred. Conclusions: In this retrospective series, navigational success comparable to published studies that adapted strict ventilation protocols was achieved with also comparable diagnostic accuracy without strict adherence to predefined ventilatory strategies. Recruitment maneuvers may represent the most influential component of current protocols, but institutional factors such as procedural expertise and case volume likely contributed to outcomes. Prospective studies are warranted to determine whether standardized ventilatory protocols are necessary for optimizing NB performance.
- 16 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1569
Open AccessRelationship Between Navigation Success, Diagnostic Accuracy, and Ventilation Strategy: Retrospective Chart Review of 224 Consecutive Navigational Bronchoscopic Procedures Performed Under General Anesthesia
Background: Navigational bronchoscopy (NB) enables precise sampling of peripheral and central pulmonary nodules using shape-sensing or electromagnetic guidance. A major challenge is anesthesia-induced atelectasis, which alters lung anatomy, reduces registration accuracy, and is known to lower diagnostic accuracy. To counteract this, ventilatory protocols such as the Ventilatory Strategy to Prevent Atelectasis (VESPA) and the Lung Navigation Ventilation Protocol (LNVP) have been recommended. Their adoption and clinical impact, however, remain uncertain. Methods: We conducted a retrospective review of 224 consecutive NB procedures performed under general anesthesia at a single academic medical center (January 2020–August 2024). Demographic, anesthetic, and ventilatory data were extracted from electronic records. Outcomes included navigational success (ability to reach the lesion) and diagnostic accuracy (concordance between bronchoscopic diagnosis and final clinical diagnosis after follow-up). Ventilatory practices were compared with published VESPA and LNVP recommendations. Results: Navigational success, defined as successful advancement of the bronchoscope to the target lesion with tissue acquisition, was achieved in 89.2% of cases. Overall diagnostic accuracy, defined as concordance between bronchoscopic diagnosis and final clinical diagnosis after follow-up, was 81.7%. Ventilatory management consistently diverged from recommended protocols. Most patients were ventilated with FiO2 > 0.6, PEEP in the range of 7–10 cm H2O, and tidal volumes of 300–500 mL. The only recommended maneuver systematically applied was recruitment immediately after intubation. Despite widespread deviation from both VESPA and LNVP, diagnostic performance remained favorable relative to published benchmarks. No major anesthesia-related complications occurred. Conclusions: In this retrospective series, navigational success comparable to published studies that adapted strict ventilation protocols was achieved with also comparable diagnostic accuracy without strict adherence to predefined ventilatory strategies. Recruitment maneuvers may represent the most influential component of current protocols, but institutional factors such as procedural expertise and case volume likely contributed to outcomes. Prospective studies are warranted to determine whether standardized ventilatory protocols are necessary for optimizing NB performance.
- 20 January 2026
- Published by Springer Nature
- p. 173-181
Anesthesia for Pleural Interventions: Thoracentesis, Pleuroscopy, and Pleurodesis
- 20 January 2026
- Published by Springer Nature
- p. 173-181
Anesthesia for Pleural Interventions: Thoracentesis, Pleuroscopy, and Pleurodesis
- Open Access
- 30 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7709
Reply to Fernández et al. Comment on “Goudra et al. Anesthesia for Bronchoscopy—An Update. J. Clin. Med. 2024, 13, 6471”
Thank you for reading our review and providing valuable feedback
- 30 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7709
Open AccessReply to Fernández et al. Comment on “Goudra et al. Anesthesia for Bronchoscopy—An Update. J. Clin. Med. 2024, 13, 6471”
Thank you for reading our review and providing valuable feedback
- Open Access
- 4 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 7028
Perioperative Repercussions of Cannabis Use—Implications for GI Endoscopy Sedation
The legalization of cannabis in multiple U.S. states and several other countries, along with its increasing social acceptance across diverse demographic and socioeconomic groups, has led to a growing number of patients presenting for interventional procedures with a history of cannabis use. Although anesthetic and sedation-related implications may be less pronounced than in major surgery, they remain clinically relevant and warrant careful consideration. Key factors include acute intoxication, chronic use, and cannabis use disorder. Cannabis users often require higher—and sometimes unpredictable—doses of propofol and other sedatives. Inhalational use is associated with airway hyperreactivity, increasing the risk of bronchospasm and, in severe cases, life-threatening laryngospasm. Acute intoxication may also impair the patient’s ability to provide informed consent. Cardiovascular manifestations, including tachycardia, hypertension, and an elevated risk of myocardial infarction, may occur depending on the timing and extent of recent cannabis exposure. Although these effects are unlikely to cause major complications during routine screening colonoscopy or diagnostic esophagogastroduodenoscopy, advanced therapeutic procedures may pose significant challenges for sedation providers. This narrative review summarizes the chemistry, pharmacology, and sedation-related implications of cannabis use in patients undergoing sedation requiring interventional procedures, with a specific focus on GI endoscopy.
- 4 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 7028
Open AccessPerioperative Repercussions of Cannabis Use—Implications for GI Endoscopy Sedation
The legalization of cannabis in multiple U.S. states and several other countries, along with its increasing social acceptance across diverse demographic and socioeconomic groups, has led to a growing number of patients presenting for interventional procedures with a history of cannabis use. Although anesthetic and sedation-related implications may be less pronounced than in major surgery, they remain clinically relevant and warrant careful consideration. Key factors include acute intoxication, chronic use, and cannabis use disorder. Cannabis users often require higher—and sometimes unpredictable—doses of propofol and other sedatives. Inhalational use is associated with airway hyperreactivity, increasing the risk of bronchospasm and, in severe cases, life-threatening laryngospasm. Acute intoxication may also impair the patient’s ability to provide informed consent. Cardiovascular manifestations, including tachycardia, hypertension, and an elevated risk of myocardial infarction, may occur depending on the timing and extent of recent cannabis exposure. Although these effects are unlikely to cause major complications during routine screening colonoscopy or diagnostic esophagogastroduodenoscopy, advanced therapeutic procedures may pose significant challenges for sedation providers. This narrative review summarizes the chemistry, pharmacology, and sedation-related implications of cannabis use in patients undergoing sedation requiring interventional procedures, with a specific focus on GI endoscopy.
- Open Access
- 14 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1978
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
The last two decades have proffered many remarkable choices in managing type 1 and type 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), the first of which, exenatide, was approved by the FDA in 2005. Two other major classes of drugs have also entered the market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins and approved in 2006, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors, with the first approval occurring in 2013. These drugs have revolutionized the treatment of diabetes. Additionally, on the horizon, the once-weekly basal insulin analog insulin icodec and the once-weekly combination of insulin icodec and semaglutide are expected to be available in the future. Beyond glycemic control, GLP1RAs have exhibited benefits in conditions associated with diabetes, including hypertension, dyslipidemia, non-alcoholic steatohepatitis, as well as in neurodegenerative diseases such as Alzheimer’s disease. Additionally, emerging research suggests potential roles in certain types of cancer, infertility, and associative learning. Major cardiovascular events seem to be lower in patients on GLP1RAs. While some evidence is robust, other findings remain tenuous. It is important that clinicians are familiar with current research in order to provide optimal evidence-based care to patients. In the not-too-distant future, there may be a case to prescribe these drugs for benefits outside diabetes.
- 14 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1978
Open AccessGlucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
The last two decades have proffered many remarkable choices in managing type 1 and type 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), the first of which, exenatide, was approved by the FDA in 2005. Two other major classes of drugs have also entered the market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins and approved in 2006, and sodium–glucose cotransporter-2 (SGLT-2) inhibitors, with the first approval occurring in 2013. These drugs have revolutionized the treatment of diabetes. Additionally, on the horizon, the once-weekly basal insulin analog insulin icodec and the once-weekly combination of insulin icodec and semaglutide are expected to be available in the future. Beyond glycemic control, GLP1RAs have exhibited benefits in conditions associated with diabetes, including hypertension, dyslipidemia, non-alcoholic steatohepatitis, as well as in neurodegenerative diseases such as Alzheimer’s disease. Additionally, emerging research suggests potential roles in certain types of cancer, infertility, and associative learning. Major cardiovascular events seem to be lower in patients on GLP1RAs. While some evidence is robust, other findings remain tenuous. It is important that clinicians are familiar with current research in order to provide optimal evidence-based care to patients. In the not-too-distant future, there may be a case to prescribe these drugs for benefits outside diabetes.
- Open Access
- 22 February 2025
- Published by Wolters Kluwer Health in Journal of Anaesthesiology Clinical Pharmacology
- Vol. 41 (2) , 226-235
Deaths and cardiac arrests during anesthesia – An analysis of 361,152 procedures in a major US health system
Background and Aims: The aim was to analyze the factors associated with intraoperative cardiac arrests at a major US academic center. Material and Methods: In this single-center university hospital setting retrospective study, perioperative cardiac arrest data obtained from the clinical quality improvement and local registry from June 1, 2013 to November 19, 2019 was analyzed. Descriptive statistics were used to analyze the findings. Results: A total of 361,152 anesthesia-requiring procedures were performed. At least 49 cardiac arrests occurred in the operating room (at a rate of 1.3 cardiac arrests for every 10,000 surgeries), of which 23 resulted in death (at a rate of 0.6 deaths for every 10,000 surgeries). Twenty-eight cardiac arrests occurred during elective procedures and the remaining were emergencies. Among the causes, hyperkalemia was seen as a likely contributory cause in six patients. PEA (Pulseless electrical activity) was the dominant rhythm and often did not precede other life-threatening arrhythmias. In terms of subspecialty, cardiac surgery witnessed the highest number of cardiac arrests followed by solid organ transplant. Nurse anesthetist/physician anesthesiologist team-delivered care was associated with intraoperative cardiac arrests, with a rate similar to that of all-physician care teams (21 vs. 28), and the death rates were similar (11 vs. 12). Highest number of cardiac arrests belonged to American Society of Anesthesiologists (ASA) 3 category. All patients who sustained cardiac arrests in ASA 2 category also died. Patients with a BMI >30.0 had the highest number of cardiac arrests, although the number of deaths was low. Conclusions: Hyperkalemia is a major factor in intraoperative cardiac arrests. Majority of the cardiac arrests occur during emergency procedures. Solid organ transplant and cardiac surgery carry the highest risk of cardiac arrests.
- 22 February 2025
- Published by Wolters Kluwer Health in Journal of Anaesthesiology Clinical Pharmacology
- Vol. 41 (2) , 226-235
Open AccessDeaths and cardiac arrests during anesthesia – An analysis of 361,152 procedures in a major US health system
Background and Aims: The aim was to analyze the factors associated with intraoperative cardiac arrests at a major US academic center. Material and Methods: In this single-center university hospital setting retrospective study, perioperative cardiac arrest data obtained from the clinical quality improvement and local registry from June 1, 2013 to November 19, 2019 was analyzed. Descriptive statistics were used to analyze the findings. Results: A total of 361,152 anesthesia-requiring procedures were performed. At least 49 cardiac arrests occurred in the operating room (at a rate of 1.3 cardiac arrests for every 10,000 surgeries), of which 23 resulted in death (at a rate of 0.6 deaths for every 10,000 surgeries). Twenty-eight cardiac arrests occurred during elective procedures and the remaining were emergencies. Among the causes, hyperkalemia was seen as a likely contributory cause in six patients. PEA (Pulseless electrical activity) was the dominant rhythm and often did not precede other life-threatening arrhythmias. In terms of subspecialty, cardiac surgery witnessed the highest number of cardiac arrests followed by solid organ transplant. Nurse anesthetist/physician anesthesiologist team-delivered care was associated with intraoperative cardiac arrests, with a rate similar to that of all-physician care teams (21 vs. 28), and the death rates were similar (11 vs. 12). Highest number of cardiac arrests belonged to American Society of Anesthesiologists (ASA) 3 category. All patients who sustained cardiac arrests in ASA 2 category also died. Patients with a BMI >30.0 had the highest number of cardiac arrests, although the number of deaths was low. Conclusions: Hyperkalemia is a major factor in intraoperative cardiac arrests. Majority of the cardiac arrests occur during emergency procedures. Solid organ transplant and cardiac surgery carry the highest risk of cardiac arrests.
- Open Access
- 24 December 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1) , 4
Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
The last two decades have provided far more options f both patients and their physicians in the treatment of diabetes mellitus. While dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been approved for nearly two decades, sodium–glucose cotransporter 2 inhibitors (SGLT-2is) are relatively new. Of interest to perioperative physicians, these drugs present specific perioperative concerns, prompting many societies to issue guidelines. Retained gastric contents due to slow gastric emptying is a significant drawback of GLP-1RAs, increasing the risk of aspiration. Recommendations include withholding GLP-1RAs for a predefined period of time, performing gastric ultrasound to evaluate gastric contents, modifying anesthesia management, particularly with regard to the airway, or canceling the scheduled (elective) surgery or procedure. SGLT-2is are known to increase the risk of euglycemic ketoacidosis. The benefits of both GLP-1RAs and SGLT-2is extend beyond the treatment of diabetes. As a result, perioperative physicians may encounter their use outside of their traditional indications. SGLT-2is are being used extensively to treat heart failure and obesity, for example. There have been other developments as well. For instance, Imeglimin, a variant of metformin available in Japan and India, Icodec, a once-weekly basal insulin formulation, and IcoSema, a once-weekly combination of Icodec plus semaglutide, are all being explored, although in their early stages or facing approval challenges.
- 24 December 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (1) , 4
Open AccessGlucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
The last two decades have provided far more options f both patients and their physicians in the treatment of diabetes mellitus. While dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been approved for nearly two decades, sodium–glucose cotransporter 2 inhibitors (SGLT-2is) are relatively new. Of interest to perioperative physicians, these drugs present specific perioperative concerns, prompting many societies to issue guidelines. Retained gastric contents due to slow gastric emptying is a significant drawback of GLP-1RAs, increasing the risk of aspiration. Recommendations include withholding GLP-1RAs for a predefined period of time, performing gastric ultrasound to evaluate gastric contents, modifying anesthesia management, particularly with regard to the airway, or canceling the scheduled (elective) surgery or procedure. SGLT-2is are known to increase the risk of euglycemic ketoacidosis. The benefits of both GLP-1RAs and SGLT-2is extend beyond the treatment of diabetes. As a result, perioperative physicians may encounter their use outside of their traditional indications. SGLT-2is are being used extensively to treat heart failure and obesity, for example. There have been other developments as well. For instance, Imeglimin, a variant of metformin available in Japan and India, Icodec, a once-weekly basal insulin formulation, and IcoSema, a once-weekly combination of Icodec plus semaglutide, are all being explored, although in their early stages or facing approval challenges.